Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|August 3, 2021
Pharmacy Clinical Pearl of the Day: A1C Levels and Diabetes
Author(s)Saro Arakelians, PharmD
Patients at risk for diabetes should try to focus on adhering to their medications, diet and exercise to reduce their blood sugars, which will decrease their A1C levels.
Advertisement
Per the guidelines from American Diabetes Association, A1C target ranges are:
- Less than 5.7% means normal
- Between 5.7% and 6.4% means prediabetes
- 6.5% or higher means diabetes
Explanation:
- If your A1C level is between 5.7 and 6.4%, your levels are in the prediabetes range.
- If you have an A1C level of 6.5% or higher, your levels are in the diabetes range.
- Patients at risk for diabetes should try to focus on adhering to their medications, diet and exercise to reduce their blood sugars, which will decrease their A1C levels.
Reference:
Advertisement
Related to this article
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5